Generating RWE for Optimising Market/Patient Access

Real-World Evidence (RWE) has become an essential addition to Randomised Controlled Trials (RCTs), helping to reduce uncertainty among regulators, payers, physicians, and patients. Yet, despite its growing importance, many pharmaceutical companies still struggle to implement RWE effectively across functions.

Success depends on a shared understanding of the fundamentals. Without a common vocabulary and baseline knowledge, cross-functional teams often face internal misalignment, slowing down RWE planning and decision-making.

This course provides a clear and practical introduction to RWE. You will learn the key concepts, study types, and use cases of real-world evidence, enabling you to contribute effectively to RWE-related decisions and projects, whether you are working directly in RWE or collaborating with RWE teams.

If you want to build a solid foundation in RWE and understand its strategic value across the product lifecycle, this course is a must-attend!

What you will learn:

1. The expectations of external stakeholders regarding RWE throughout the product lifecycle.

2. The fundamental concepts, methodologies, and research techniques of RWE in the context of optimising Market Access.

3. Types of data and their strengths & weaknesses.

4. Critical success factors of an RWE study.

5. How to prepare for new developments in RWE generation.

THE EXPERT
Prof. Dr Thomas Wilke is a recognised expert in real-world evidence generation and an experienced academic.